Benzodiazepines are widely used in clinics and for recreational purposes, but will lead to addiction in vulnerable individuals. Addictive drugs increase the levels of dopamine and also trigger long-lasting synaptic adaptations in the mesolimbic reward system that ultimately may induce the pathological behaviour. The neural basis for the addictive nature of benzodiazepines, however, remains elusive. Here we show that benzodiazepines increase firing of dopamine neurons of the ventral tegmental area through the positive modulation of GABA A (c-aminobutyric acid type A) receptors in nearby interneurons. Such disinhibition, which relies on a1-containing GABA A receptors expressed in these cells, triggers drug-evoked synaptic plasticity in excitatory afferents onto dopamine neurons and underlies drug reinforcement. Taken together, our data provide evidence that benzodiazepines share defining pharmacological features of addictive drugs through cell-type-specific expression of a1-containing GABA A receptors in the ventral tegmental area. The data also indicate that subunit-selective benzodiazepines sparing a1 may be devoid of addiction liability.
Addictive drugs can be classified into three groups, according to the cellular mechanism through which they increase mesolimbic dopamine (DA) 1 . Opioids, cannabinoids and the club drug c-hydroxybutyrate reduce release from inhibitory afferents onto DA neurons, through their respective G-protein-coupled receptors on GABA neurons. These substances activate pre-and postsynaptic receptors, indirectly increasing the firing rate of DA neurons, a mechanism defined as disinhibition. Nicotine, as a member of the second group, directly depolarizes DA neurons by activating a 4 b 2 -containing acetylcholine receptors, whereas the third group targets DA transporters (for example, cocaine and amphetamines). It remains unclear whether these mechanisms can account for the addiction liability of benzodiazepines (BDZs) 2 , which are positive modulators of GABA A receptor (GABA A R) function.
As well as increasing mesolimbic DA, another common feature of all addictive drugs studied so far is that they trigger adaptive synaptic plasticity in the ventral tregmental area (VTA) 3 . Hours after the initial exposure, excitatory afferents onto DA neurons of the VTA are strengthened, in part by the insertion of GluR2-lacking AMPARs (aamino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors) [4] [5] [6] . To test whether a similar mechanism is elicited by BDZs, we examined whether a single injection of BDZ would, as well as causing an increase in the AMPA/NMDA ratio 7 , also induce a change in the slope of the current-voltage (I-V)-curve of evoked excitatory postsynaptic currents (EPSCs). Such rectification reflects the presence of GluR2-lacking AMPARs, which are calcium permeable and blocked by polyamines at positive potentials.
BDZ-evoked plasticity in dopamine neurons
In slices obtained 24 h after the intraperitoneal (i.p.) injection of midazolam (MDZ), diazepam or flunitrazepam, the rectification index (RI 5 EPSC 265 mV /EPSC 135 mV ) was significantly higher than in slices from saline-injected controls ( Fig. 1a and Supplementary Fig. 2 ). Similar rectification was measured after an injection of morphine, a member of the class of drugs that cause disinhibition of DA neurons 8 . The BDZ antagonist flumazenil blocked rectification when co-injected with MDZ, but was without effect when co-injected with a control saline solution ( Fig. 2 and Supplementary Fig. 2 ). The adaptive plasticity induced by systemic BDZs was also observed 24 h after local application of MDZ into the VTA by stereotactic injection (0.5 ml of an 8 mg ml 21 solution over 10 min; Fig. 1b ). Thus, BDZ-dependent effects on VTA circuitry are sufficient to induce this cellular hallmark of addictive drugs.
BDZs bind to GABA A Rs at the interface between a and c subunits 9 in a subunit-dependent manner. GABA neurons in many parts of the brain express the a1 subunit isoform 10 , whereas midbrain DA neurons lack a1 but express a2, a3 and a4 subunit isoforms 11 . Thus, the addictive potential of BDZs might rely on the potentiation of a1-containing GABA A Rs, which would selectively inhibit GABA neurons and lead to disinhibition of DA neurons. To test this idea, we examined whether MDZ (that is, a rapidly acting, non-selective BDZ with a very strong brain uptake 12 ) has an effect in mice with a point mutation (H101R) in the a1 subunit that disrupts the site where BDZs normally bind 13 . In a1(H101R) mice, an i.p. MDZ injection no longer had an effect on the rectification index of AMPAR EPSCs in DA neurons ( Fig. 1c ). This was not due to a general loss of adaptive plasticity, as morphine still caused a strong rectification. Moreover, stereotactic injections of MDZ into the VTA also failed to elicit rectifying AMPAR-mediated EPSCs in a1(H101R) mice, whereas control injections of artificial cerebrospinal fluid (ACSF) were without effect in either genotype ( Fig. 1d ). Furthermore, i.p. injection of MDZ increased the AMPA/NMDA ratio in wild-type but not in a1(H101R) mice ( Supplementary Fig. 3 ).
We next used pharmacological tools to confirm the involvement of a1. Zolpidem (ZOL) is a non-classical BDZ selective for a1-containing GABA A Rs 14 , whereas the experimental compound L-838 417 does not modulate receptors that contain a1 (ref. 15 ). We therefore tested whether ZOL and L-838 417 could evoke synaptic plasticity in DA neurons. We found that a single injection of ZOL led to rectifying AMPAR-mediated EPSCs, whereas L-838 417 did not affect the I-V curve (Fig. 2 ). Taken together with the results in a1(H101R) mice described earlier, we conclude that BDZ-evoked synaptic plasticity depends on a1-containing GABA A Rs within the VTA.
Cell type-specific expression of a1
To identify a1-expressing cells in the VTA, we next carried out immunohistochemical staining for tyrosine hydroxylase and the a1 subunit isoform in GAD67 green fluorescent protein (GFP) mice ( Fig. 3a) . These experiments confirmed that a1 was expressed mainly in GFP-positive neurons, but not in tyrosine-hydroxylase-positive DA neurons. Quantification showed that 81% of the GABA neurons contained the a1 subunit isoform, although this was only the case in 7% of the DA neurons ( Fig. 3a , inset). We also observed a1-staining that could neither be associated to tyrosine-hydroxylase-positive nor GAD67-GFP-expressing cells. This may reflect the pool of the socalled tertiary cells that are neither DA-nor GABA-neurons 16, 17 , or could be due to detectability limits in fine processes.
To assess the functional consequences of this cell-type-specific isoform expression for inhibitory transmission, we characterized miniature inhibitory postsynaptic currents (mIPSCs) in the presence of the glutamate receptor blocker kynurenic acid to isolate GABA A Rmediated currents (Fig. 3b , c). On average, mIPSCs in GABA neurons were slower and bigger than those in DA neurons, leading to a significantly larger charge transfer in the former (Fig. 3d ). This difference was of similar magnitude in wild-type and a1(H101R) mice ( Supplementary Fig. 4 ), in line with previous reports 13 that baseline transmission in mutant mice is normal. Moreover, the frequency of mIPSCs, as well as the multiplicity factor ( Supplementary Fig. 4c and see Methods for detailed description), were similar in GABA and DA neurons in both genotypes. Although this approach has its limitations 18 , it suggests that the number of inhibitory synapses is in the same range in the two cell types. To confirm further that synapses on GABA neurons express a1-containing GABA A Rs, we tested for effects of MDZ on charge transfer and frequency of mIPSCs in wild-type and a1(H101R) mice. In DA neurons, MDZ significantly increased the charge transfer and decreased the mIPSC frequency in both genotypes. In GABA neurons, MDZ increased the charge transfer and decreased mIPSC frequency in slices from wild-type mice, but was without effect on mIPSCs recorded in slices from a1(H101R) mice (Fig. 3e, f and Supplementary Fig. 5a ). As expected, MDZ had no effect on mIPSC amplitude in either cell type or genotype 19 ( Supplementary Fig. 5b ). The observation that the mIPSC frequency is reduced by BDZs except in GABA neurons of a1(H101R) mice is surprising at first, but could reflect presynaptic GABA A Rs. In fact, such receptors have been described in the VTA, which after activation reduce the release probability 20 . Because DA neurons express a set of many subunit isoforms 11 , the identification of the molecular composition of the GABA A Rs is difficult. Most DA neurons actually express the a3 subunit isoform (96%, Supplementary Fig. 6 ). Notably, most GABA neurons do not express the a3 subunit isoform (70%) even though significant heterogeneity was observed. In heterologous expressed systems, currents of a1-containing receptors are smaller than those of a3-containing receptors 21 . This, however, does not apply to DA neurons in the VTA, because in a3 knockout mice currents are reduced by only 50% 22 . Our results establish that in a1(H101R) mice, endogenous GABA A -mediated synaptic transmission is normal, whereas the positive modulation of MDZ is abolished in GABA neurons, because the a1 subunit isoform is selectively expressed in these cells.
Cellular determinants of disinhibition
In wild-type mice, mIPSCs in both GABA and DA neurons were enhanced by BDZs. However, when BDZs are administered while transmission is intact, the extent of current amplification in DA neurons depends on the frequency of synaptic events, which originate in the interneurons upstream. We therefore monitored the effect of MDZ on spike-driven, spontaneous IPSCs (sIPSCs) in DA neurons ( Fig. 4) . Although, the charge transfer of sIPSCs on average increased after MDZ (in line with the mIPSC data), there was a strong reduction of the frequency of spike-driven events in DA neurons ( Supplementary  Fig. 7) . As a result, when we integrated the charge transfer of sIPSCs over time before and after the application of MDZ (relative total current), we found a significant decrease (Fig. 4b ). Because interneurons are efficiently inhibited by MDZ, fewer spikes are generated, strongly decreasing the number of sIPSCs, an effect that predominates over the MDZ amplification of the individual event. In a1(H101R) mice, in contrast, we observed an increased total current in DA neurons because the GABA neurons were insensitive to MDZ. In summary, in wild-type ARTICLES mice, MDZ led to a net decrease of the total inhibitory current in DA neurons, which could be sufficient to cause their disinhibition (see Supplementary Fig. 1 for schematics). We therefore tested the effect of MDZ on the firing rate of DA neurons in the VTA by performing extracellular single-unit recordings in vivo. When the drug was injected into the tail vein of wild-type mice, we recorded a significant increase in the firing rate that was reversed by flumazenil ( Fig. 5a , e, g). In stark contrast, no such disinhibition could be observed in a1(H101R) mice ( Fig. 5b, e, g) . In line with a disinhibition model, the data in the DA neurons were mirrored by the observations in GABA neurons. MDZ caused an inhibition of the spontaneous firing rates, at times leading to complete spike suppression ( Fig. 5c, f, g) . In a1(H101R) mice, MDZ did not significantly affect firing in GABA neurons (Fig. 5d, f, g) . The specificity of these findings are further demonstrated by the observation that in mice in which a different a subunit isoform had been mutated (a3(H126R) mice) 23 , MDZ caused an increase in the firing rate of DA neurons comparable to wild-type mice ( Supplementary Fig. 8 ). The magnitude of this increase was inversely related to the basal firing rate, which further indicates a disinhibition model (Fig. 5e ). Moreover, in a1(H101R) mice, disinhibition of DA neurons was observed with morphine, an effect that was also inversely correlated to the basal firing rate (Fig. 5h ). Although anaesthesia may modify the overall distribution of firing rates and therefore the magnitude of the disinhibition, the mean basal firing rates observed here were comparable to values recorded in freely moving animals 24, 25 .
Self-administration of midazolam
The results demonstrate that a1-containing GABA A Rs mediate the increase of mesolimbic DA in response to BDZs. Furthermore, DA antagonists can reduce self-administration of and preference to these drugs 26, 27 . We therefore tested the effect of the a1 subunit isoform on oral self-administration of MDZ, by offering the mice a free choice of two drinking solutions (Fig. 6a ). During the first 3 days the two bottles contained water. Sucrose was then added to both bottles to mask any bitter tastes. This led to an increase in the overall consumption, but no particular preference. Finally, MDZ was added to one of the two bottles. During the test period with MDZ, the total consumption did not change in either genotype (Fig. 6b) . A preference for the MDZ solution developed rapidly in wild-type mice, but not in a1(H101R) mice (Fig. 6c, d) . Wild-type mice drank between 0.8 and 1.1 mg kg 21 per 24 h of MDZ, which corresponds to a pharmacological dose. Two control experiments were carried out using a similar protocol. First, we offered a1(H101R) mice a choice between water and sucrose solution. Both wild-type and mutant mice developed a strong preference for sucrose, indicating that a1(H101R) mice are not generally deficient in reward reinforcement ( Supplementary Fig. 9 ). We also tested whether a3(H126R) mice, in which MDZ caused a normal disinhibition of DA neurons ( Supplementary Fig. 8 ), would develop a preference for MDZ, which was indeed the case (Supplementary Fig. 10 ). Although BDZs, particularly MDZ, may enhance taste perception 28 , this is unlikely to influence the interpretation of these data, as several studies have shown that BDZ-mediated taste enhancement is independent of a1-containing GABA A Rs 29, 30 .
Discussion
On the basis of our data, we propose that BDZs increase DA levels through disinhibition, similar to opioids, cannabinoids and c-hydroxybutyrate. This disinhibition is dependent on the BDZbinding site on a1-containing GABA A Rs in the VTA. The net effect of BDZs on the VTA circuit is dominated by the role of a1-containing GABA A Rs, which is supported by the following three observations. First, GABA A R-mediated quantal transmission is stronger in GABA neurons than in DA neurons, as evidenced by the larger charge transfer of mIPSCs (Fig. 3d ). Second, GABA neurons have a higher input resistance than DA neurons 17 , allowing the same charge transfer to more effectively change the membrane potential of GABA neurons than DA neurons. Third, the BDZ-dependent enhancement of each IPSC on DA neurons causes little inhibition of DA neuron activity because GABA neurons fall silent and no longer generate those IPSCs. Our model could also apply to earlier work probing the effect of the GABA A R-agonist muscimol 31 . When administered directly into the VTA, muscimol causes an increase of DA levels in the nucleus accumbens 32 . This effect only occurs at low doses, which led to the conclusion that the effect is mediated indirectly on non-DA neurons 33, 34 . This inverse dose-dependence may be due to the fact that muscimol, unlike BDZs, is not a positive modulator but an agonist. In line with this interpretation, muscimol at high concentrations in fact inhibits DA neurons 35 .
The implication of a1 in the addictive effect of BDZs is surprising because the clinically available compound ZOL is selective for this subunit and has been claimed to carry a low risk for addiction 36 . However, this optimistic view contrasts with the observation that ZOL is readily self-administered 37 and the clinical reality. Our data with the subunit isoform-selective compounds also show that ZOL triggers drug-evoked plasticity, and indicate that a1-sparing compounds may be promising candidates in the search for BDZs devoid of addiction liability. Because a1-containing GABA A Rs outside the VTA mediate other effects such as seizure control, sedation and anterograde amnesia 38 , a1-sparing compounds will certainly not be suitable for all indications. The dissociation between anxiolysis, mainly a2-mediated 23 , and addiction, however, seems possible in principle. This is particularly appealing as high anxiety levels suggest increased vulnerability for addiction 39 .
Our work unravels the molecular basis of the defining pharmacological features that BDZs share with addictive drugs, which we believe will be key for designing new BDZs with lower addiction liability. However, we note that increased levels of mesolimbic dopamine are necessary for addiction, but not sufficient on their Figure 4 | The total current generated by sIPSCs in DA neurons is decreased by MDZ. a, Example trace of sIPSC recordings in GABA and DA neurons obtained before and after application of MDZ in slices from wildtype and a1(H101R) mice. sIPSCs were abolished with picrotoxin (100 mM, not shown). b, Group data for the relative increase in the overall charge transfer (1 min) after MDZ bath-application. Note that in wild-type mice the total current in DA neurons decreases with MDZ application, whereas in a1(H101R) mice there is an increase. GABA/WT versus GABA/a1(H101R) t (9) 5 6.39, DA/WT versus DA/a1(H101R) t (15) 5 5.50; n 5 6-7. Box plot designations are as in Fig. 3d ; ***P , 0.001.
own. Recent studies suggest that early drug-evoked plasticity in the VTA may facilitate addiction by gating more enduring forms of adaptations in target regions of the mesolimbic system, which would represent the eventual locus underlying long-term addictive behaviours 40, 41 . Coinciding factors of vulnerability, either in the initial events in the VTA or in subsequent events in mesolimbic targets, may ultimately explain individual variations in susceptibility to addiction, both for BDZs and for other drugs 42 .
METHODS SUMMARY
Horizontal slices of the midbrain (250 mm) were prepared as previously described 43 from C57BL/6 mice, Pitx3-GFP knock-in mice 44 , GAD67-GFP Dneo mice 45 and a1(H101R) knock-in mice 13 In vivo extracellular single-unit recordings of DA neurons in the VTA (ML: 21.2, AP: 23.2, DV: 24 to 4.5 mm from the bregma) were carried out in wild-type, a1(H101R) and a3(H126R) 23 knock-in mice. Drugs were delivered through the tail vein. Immunofluorescence with a guinea-pig antibody against the a1 or a3 subunit, a mouse antibody against tyrosine hydroxylase, and a rabbit antibody against enhanced GFP (eGFP) was performed as previously described 10 in GAD67-GFP Dneo mice. For the oral self-administration of MDZ, mice were housed with free access to two bottles containing either MDZ in sucrose or sucrose alone. Grouped data are expressed as means 6 s.e.m. For statistical comparisons the one-way analysis of variance (ANOVA), Bonferroni matched, or the paired Student's t-tests were used. The levels of significance are indicated as follows: *P , 0.05, **P , 0.01 and ***P , 0.001. .63. f, Corresponding plot with the results obtained in GABA neurons. Note that three out of five neurons were completely silenced, which precluded fitting. g, Box plots representing group data for relative change in firing rate. Wild-type DA/a1(H101R) DA t (23) 5 2.70, wild-type GABA/a1(H101R) GABA t (12) experiment. b, Total consumption successively with water, sucrose and MDZ (0.005 mg ml 21 ) plus sucrose (4%) in wild-type mice (black) and a1(H101R) (red) mice. Note that wild-type and a1(H101R) mice drink similar amounts of liquids. c, Relative MDZ consumption in wild-type and a1(H101R) mice. d, Corresponding box plots for relative average consumption of MDZ at days (D) indicated. n 5 12-18 mice in 4-6 cages; F (3;16) 5 5.39. Box plot designations are as in Fig. 3d ; **P , 0.01.
